Related Experiment Video
Updated: Jun 25, 2026

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography
Published on: September 22, 2011
SERCA inhibition limits the functional effects of cyclic GMP in both control and hypertrophic cardiac myocytes
Qihang Zhang1, Tomer Davidov, Harvey R Weiss
1Heart and Brain Circulation Laboratory, Department of Physiology and Biophysics, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ 08903-0019, USA.
Insights
In cardiac hypertrophy, cyclic GMP
Area of Science:
- Cardiovascular Physiology
- Cellular Biology
Background:
- Cyclic GMP (cGMP) normally regulates cardiac myocyte function.
- In cardiac hypertrophy, the effects of cGMP are diminished.
- The sarcoplasmic reticulum calcium-ATPase (SERCA) is implicated in cGMP signaling.
Purpose of the Study:
- To investigate the hypothesis that the interaction between cGMP and SERCA is reduced in hypertrophic cardiac myocytes.
- To determine if SERCA activity influences the blunted response to cGMP in hypertrophy.
Main Methods:
- Myocytes were isolated from control and hypertrophic rabbits.
- Cells were treated with 8-bromo-cGMP (8-Br-cGMP) alone or after SERCA inhibition with thapsigargin or cyclopiazonic acid (CPA).
- Myocyte shortening, relaxation, and intracellular calcium transients were measured.
Main Results:
- 8-Br-cGMP significantly decreased shortening in control myocytes but had a smaller effect in hypertrophic myocytes.
- SERCA inhibition blunted the effects of 8-Br-cGMP in control myocytes.
- In hypertrophic myocytes, SERCA inhibition abolished the response to 8-Br-cGMP.
- Intracellular calcium dynamics mirrored functional changes.
Conclusions:
- The blunted response to cGMP in hypertrophic myocytes is not directly related to SERCA.
- SERCA inhibition affects cGMP responses in both control and hypertrophic myocytes, suggesting complex interactions.
Abstract:
The negative functional effects of cyclic GMP are controlled by the sarcoplasmic reticulum calcium-ATPase (SERCA). The effects of cyclic GMP are blunted in cardiac hypertrophy. We tested the hypothesis that the interaction between cyclic GMP and SERCA would be reduced in hypertrophic cardiac myocytes. Myocytes were isolated from 7 control and 7 renal-hypertensive hypertrophic rabbits. Control and hypertrophic myocytes received 8-bromo-cGMP (8-Br-cGMP; 10(-7), 10(-6), 10(-5) mol/l), the SERCA blocker thapsigargin (10(-8) mol/l) followed by 8-Br-cGMP, or the SERCA blocker, cyclopiazonic acid (CPA; 10(-7) mol/l) followed by 8-Br-cGMP. Percent shortening and maximal rate of shortening and relaxation were recorded using a video edge detector. Changes in cytosolic Ca2+ were assessed in fura 2-loaded myocytes. In controls, 8-Br-cGMP caused a significant 36% decrease in percent shortening from 5.8 +/- 0.4 to 3.7 +/- 0.3%. Thapsigargin and CPA did not affect basal control or hypertrophic myocyte function. When 8-Br-cGMP was given following thapsigargin or CPA, the negative effects of 8-Br-cGMP on control myocyte function were reduced. In hypertrophic myocytes, 8-Br-cGMP caused a smaller but significant 17% decrease in percent shortening from 4.7 +/- 0.2 to 3.9 +/- 0.1%. When 8-Br-cGMP was given following thapsigargin or CPA, no significant changes occurred in hypertrophic cell function. Intracellular Ca2+ transients responded in a similar manner to changes in cell function in control and hypertrophic myocytes. These results show that the effects of cyclic GMP were reduced in hypertrophic myocytes, but this was not related to SERCA. In presence of SERCA inhibitors, the responses to cyclic GMP were blunted in hypertrophic as well as control myocytes.
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
Two...
G-Protein Gated Ion Channels
Sensory organs,...
cAMP-dependent Protein Kinase Pathways
GPCR Desensitization
Global Regulatory Systems
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

